Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). by Stephenson, Terence et al.
1Stephenson T, et al. BMJ Open 2021;11:e052838. doi:10.1136/bmjopen-2021-052838
Open access 
Long COVID and the mental and 
physical health of children and young 
people: national matched cohort study 
protocol (the CLoCk study)
Terence Stephenson   ,1 Roz Shafran,1 Bianca De Stavola,1 Natalia Rojas   ,1 
Felicity Aiano,2 Zahin Amin- Chowdhury   ,2 Kelsey McOwat,2 Ruth Simmons,2 
Maria Zavala,2 CLoCk Consortium,1 Shamez N Ladhani,2 CLoCk Consortium 
members
To cite: Stephenson T, 
Shafran R, De Stavola B, et al.  
Long COVID and the mental 
and physical health of children 
and young people: national 
matched cohort study protocol 
(the CLoCk study). BMJ Open 
2021;11:e052838. doi:10.1136/
bmjopen-2021-052838
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2021- 
052838).
Received 06 May 2021
Accepted 30 July 2021
1Population, Policy and Practice, 
UCL Great Ormond Street 
Institute of Child Health, London, 
UK
2Immunisation Department, 
Public Health England, London, 
UK
Correspondence to
Professor Terence Stephenson;  
 T. Stephenson@ ucl. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction There is uncertainty surrounding the 
diagnosis, prevalence, phenotype, duration and treatment 
of Long COVID. This study aims to (A) describe the clinical 
phenotype of post- COVID symptomatology in children 
and young people (CYP) with laboratory- confirmed SARS- 
CoV-2 infection compared with test- negative controls, (B) 
produce an operational definition of Long COVID in CYP, 
and (C) establish its prevalence in CYP.
Methods and analysis A cohort study of SARS- CoV-2- 
positive CYP aged 11–17 years compared with age, sex 
and geographically matched SARS- CoV-2 test- negative 
CYP. CYP aged 11–17 testing positive and negative for 
SARS- CoV-2 infection will be identified and contacted 3, 
6, 12 and 24 months after the test date. Consenting CYP 
will complete an online questionnaire. We initially planned 
to recruit 3000 test positives and 3000 test negatives 
but have since extended our target. Data visualisation 
techniques will be used to examine trajectories over 
time for symptoms and variables measured repeatedly, 
separately by original test status. Summary measures of 
fatigue and mental health dimensions will be generated 
using dimension reduction methods such as latent 
variables/latent class/principal component analysis 
methods. Cross- tabulation of collected and derived 
variables against test status and discriminant analysis will 
help operationalise preliminary definitions of Long COVID.
Ethics and dissemination Research Ethics Committee 
approval granted. Data will be stored in secure Public 
Health England servers or University College London’s 
Data Safe Haven. Risks of harm will be minimised by 
providing information on where to seek support. Results 
will be published on a preprint server followed by journal 
publication, with reuse of articles under a CC BY licence. 
Data will be published with protection against identification 
when there are small frequencies involved.
Trial registration number ISRCTN34804192; Pre- results.
INTRODUCTION
Currently, there is huge uncertainty 
surrounding the diagnosis, prevalence, 
phenotype, duration and treatment of Long 
COVID. There is currently no diagnostic test 
or code for Long COVID. Consequently, cases 
of Long COVID are not captured in routine 
National Health Service (NHS) administrative 
data sets. Instead, Long COVID may be coded 
as a variety of different conditions in hospital 
or symptom clusters in non- hospitalised chil-
dren and young people (CYP). However, 
it is possible the symptoms associated with 
Long COVID are in fact a mixture of factors 
relating to the pandemic and lockdown as a 
whole rather than the viral infection itself. 
For example, factors such as social isolation, 
anxiety, depression or educational concerns 
may be the root cause of these symptoms in 
CYP both with and without SARS- CoV-2 infec-
tion. The effects on the developing brain 
and behaviour of adolescents could be far 
reaching.1
Strengths and limitations of this study
 ► This study does not start with an arbitrary definition 
of a new condition—‘opinion- based medicine’.
 ► Rather it represents ‘evidence- based medicine’—
we will seek the views of children and young people 
on what they have experienced physically and men-
tally in the months following COVID-19.
 ► The study incorporates a comparator matched 
cohort of children and young people who have ex-
perienced a pandemic, school closure and social 
isolation but who had a negative COVID-19 test.
 ► The comparator matched cohort of children and 
young people must also have had a reason to seek 
a COVID-19 test: symptoms, anxiety, a contact or a 
bereavement.
 ► Ideally, we would test all children for antibodies 
to confirm COVID-19 positive and negative status 
throughout the study period but we thought this 
would significantly reduce participation.
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Despite acute COVID-19 illness being milder in CYP, 
it should not be assumed that those CYP at low risk of 
life- threatening acute infections2 3 do not suffer the 
longer term consequences of SARS- CoV-2 infection. It is 
important to study Long COVID within this population 
given that the psychological and social impact of Long 
COVID could have major consequences for transition to 
adulthood. There is a clear need to define the clinical 
phenotype of Long COVID in order to understand those 
most at risk, the illness trajectory, and to provide accurate 
information on the natural course of the condition. It is 
equally important to understand both the physical and 
mental health impact on CYP with Long COVID, given 
the rise in mental health problems among CYP since the 
start of the pandemic.4 Obtaining a better understanding 
of which CYP are affected will help with targeting poten-
tial interventions.
The greatest risk factor for SAR- CoV-2 illness has been 
old age, with other risk factors at all ages including 
obesity, comorbid long- term conditions, learning and 
neurological disabilities, mental health problems and 
ethnic minority status. It is plausible that such CYP may 
be most at risk of suffering from Long COVID, given that 
much is still unknown in CYP about the immunological 
susceptibility and underlying biology of Long COVID. Of 
all CYP, those likely to be most at risk of Long COVID 
are teenagers, with existing literature showing they make 
up the majority of CYP with chronic fatigue, post viral 
syndromes and persistent symptoms.5
In adults, there is emerging evidence that gender is a risk 
factor for Long COVID, with middle- aged females more 
susceptible than men.6 In terms of symptoms, two main 
groupings have been identified: (1) respiratory symptoms 
(eg, cough, shortness of breath) as well as fatigue and head-
aches, and (2) multisystem, including the brain, gut and 
heart. Among adults with Long COVID, heart symptoms 
such as palpitations or fast heartbeat, pins and needles or 
numbness and problems concentrating (‘brain fog’) have 
been reported. Experiencing a greater number of symp-
toms during the first week of infection, as well as older age, 
has also been linked to Long COVID. It should be noted 
mental health conditions were not reported in this cohort. 
Four syndromes have been described in adults: postviral 
fatigue; fluctuating multisystem symptoms; postintensive 
care syndrome; and lasting organ damage. It is known in 
both adults and young people that a wide range of long- 
term physical conditions increase the risk of mental ill 
health, particularly if the condition involves the central 
nervous system, with several studies reporting increased 
rates of all common mental health conditions in children.7 
Moreover, fatigue has also been studied in paediatric long- 
term conditions including CYP with multiple sclerosis.8 9 
Emerging clinical observations and preliminary research 
indicate that COVID-19 can have a long- term impact on 
CYP in a range of domains10 11 but well- conducted, meth-
odologically robust studies are lacking.
This study primarily aims to (A) describe the clinical 
phenotype and prevalence of post- COVID-19 symptoms 
(eg, pain or physical symptoms, fatigue, sleep prob-
lems, mental health problems) among test- positive CYP 
compared to test- negative CYP, (B) produce an opera-
tional definition of Long COVID in CYP, and (C) estab-
lish the prevalence of Long COVID in CYP testing positive 
for SARS- CoV-2 infection. The second aim is of particular 
importance given that this is a prerequisite for any future 
epidemiological or interventional study. This will be 
achieved by using the empirical data we will acquire from 
17 000 CYP and a national Delphi consensus process.
METHODS
Study design and setting
Public Health England (PHE) has been conducting 
national surveillance of SARS- CoV-2 since the start of the 
pandemic in England. PHE receives daily electronic noti-
fications of all SARS- CoV-2 RT- PCR tests performed in 
healthcare settings (Pillar 1 tests) and in the community 
(Pillar 2 tests), which are reported through the Second 
Generation Surveillance System (SGSS). Information 
within the SGSS reports includes NHS number, name, 
age, sex, postcode, date of sample, reporting laboratory 
and test result. PHE also has access to the electronic 
Patient Demographic Service (PDS), which contains the 
names, addresses and status (alive/dead) of all patients 
registered with the NHS.
A sample of CYP aged 11–17 years when testing positive 
for SARS- CoV-2 between September 2020 and March 2021 
and COVID-19 test- negative CYP matched for age, sex 
and region identified through SGSS will be linked to PDS 
using available identifiers and postal addresses. A letter 
will be posted to them, informing them about the study 
and inviting them to take part using an online link. This 
link will provide them with information about the study, 
with an option to consent online and complete a short 
recruitment questionnaire (or both as paper options). 
Recruitment was planned to start in March 2021 and all 
data collection anticipated to end in April 2023.
This will be a cohort study of SARS- CoV-2 test- positive 
CYP aged 11–17 years matched on the test date, age, sex 
and geography to SARS- CoV-2 test- negative controls iden-
tified by PHE.
Participants
Between September 2020 and March 2021, a total of 234 
803 CYP aged between 11 and 17 years were diagnosed 
with COVID-19 in England. During the same period there 
were 1 481 154 negative tests among this age group equiv-
alent to 1 203 996 CYP. Among those who tested negative 
76 689 individuals (100 154 tests) were excluded as they 
had a positive result before and/or after their negative 
test. The positive and negative cohorts were linked using 
age at test, gender, month of test and lower super output 
area resulting in 102 402 positive individuals and 147 561 
negative individuals. Matched individuals were checked 
against the NHS spine to exclude any individuals who 
have died, and to extract participants’ addresses to send 
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invitation letters. Thirty- seven individuals were excluded 
because they had died since their COVID-19 test (six 
among those positive and 31 among those negative), 
and 11 193 individuals of the positive cohort and 19 251 
individuals of the negative cohort were excluded as an 
address was not available. Finally, 187 CYP were excluded 
as they were included in a previous study. Following exclu-
sions, 91 016 positive CYP and 128 220 negative CYP will 
be available to be invited to participate in the study. For 
all the months except December, all eligible individuals 
will be sent an invitation. For those tested in December, 
2970 positive CYP and 5911 negative CYP will be invited as 
the eligible number was so large that additional funding 
would be needed to invite all those eligible.
This is shown schematically in figure 1.
Data collection
Participating families of CYP will be contacted 3, 6, 12 and 
24 months after the CYP’s SARS- CoV-2 test (depending 
on recruitment month) and invited to take part in the 
study. Following online informed consent, the CYP will 
self- complete an online (or paper) questionnaire about 
their mental and physical health. CYP towards the lower 
end of the 11–17 age band and CYP with special educa-
tional needs or disability may require the help of a carer 
to complete the questionnaire.
Outcomes
The questionnaires given to CYP include elements of the 
International Severe Acute Respiratory and emerging 
Infection Consortium (ISARIC) Paediatric COVID-19 
follow- up questionnaire12 and the recent Mental Health of 
Children and Young People in England surveys13 to facil-
itate international comparisons regarding the risk factors 
and profile of Long COVID in CYP. The questionnaires 
given to CYP were designed together with the ISARIC 
Paediatric Working Group to produce a harmonised data 
collection tool, allowing for standardisation and meta- 
analysis by design.
The elements taken from the ISARIC Paediatric 
COVID-19 follow- up questionnaire12 include ques-
tions about demographics and physical symptoms, with 
particular questions enquiring about cough and fever, 
given that these are the main acute symptoms in non- 
hospitalised CYP14 and gastrointestinal symptoms, as a 
study has shown such symptoms were common in sero-
positive CYP.15 It is likely other symptoms will manifest 
later in Long COVID (eg, tiredness, headaches, myalgia, 
etc), with the skin rashes and cardiac problems in hospi-
talised children with paediatric multisystem inflamma-
tory syndrome being borne in mind for Long COVID.5 
Those older CYP could very well overlap with adult 
symptomatology (eg, a neuropsychiatric- encephalitic 
subgroup).
In terms of the other questions, the Strengths and Diffi-
culties Questionnaire16 will be used to assess emotional 
and mental health, consisting of 25 items. The EuroQol 
Group, 5- Dimension health- related quality of life instru-
ment for Young people (EQ- 5D- Y)17 will be used as a 
measure of quality of life/functioning, with fatigue 
measured using the 11- item Chalder Fatigue Question-
naire.18 Additionally, the short 7- item version of the 
Warwick- Edinburgh Mental Well- being Scale19 will be 
included. Loneliness will be measured using the 4- item 
UCLA (University of California at Los Angeles) Loneli-
ness Scale for Children20 as well as self- reported school 
attendance.
The length of the online self- assessment has an esti-
mated completion time of approximately 20 min for 
CYP. The CYP do not have to complete all of the ques-
tions at once but can pause and save the answers at any 
point.
Statistical analyses
Response rates for positive and negative CYP will inform 
expectations of final study size and possibly refinement 
of the sampling percentages. Descriptive statistics will 
be used for all dimensions collected at baseline and the 
follow- up questionnaires, separately by test status, wave 
and month of test. Appropriate data visualisation tech-
niques will be used to examine trajectories over time for 
those variables that are measured repeatedly, separately 
by test status and month of test. Summary measures of 
the fatigue and mental health dimensions will be gener-
ated using dimension reduction methods such as latent 
variables/latent class/principal component analysis 
methods. Cross- tabulation of latent variables against test 
status as well as discriminant analysis will help opera-
tionalise preliminary definitions of Long COVID. These 
will be compared with definitions based on categorisa-
tion of prolonged symptoms supplemented by a Delphi 
consensus process.
Figure 1 Flow chart of the selection process. CYP, children 
and young people.
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Sample size
A total of 5000 participants (2500 test positive and 2500 
test negative) would give 80% power to detect at least a 4% 
difference in symptoms at 5% significance, if the COVID-
19- negative participants had a prevalence similar to that 
reported for adults (ie, 34%). Greater baseline preva-
lences (eg, 40%) would require slightly greater numbers 
for the same power and confidence; smaller baseline prev-
alences (eg, 20%) smaller numbers. However, identifying 
risk factors for Long COVID-19 would require studying 
demographic, social, family and clinical data and thus we 
would require larger numbers. For this reason, we are 
planning to invite all available participants.
Patient and public involvement
Resources have been allocated for any patient and public 
involvement (PPI) activities at INVOLVE (a national advi-
sory body funded by the National Institute for Health 
Research to support public involvement in NHS, public 
health and social care research and development) rates 
including a nationally representative PPI research advi-
sory group. PPI members will be offered training and 
support in accordance with the INVOLVE21 report and 
other guidance22 including online training. PPI meetings 
will take place quarterly.
ETHICS AND DISSEMINATION
Ethical considerations
PHE has legal permission, provided by Regulation 3 of 
The Health Service (Control of Patient Information) 
Regulations 2002, to process patient confidential infor-
mation for national surveillance of communicable 
diseases. Individual patient consent is not required for 
initial invitation to the study. Parents/carers and young 
people will be sent an invitation with a link to the website 
with the relevant information sheets and consent forms. 
They will have the opportunity to ask any questions about 
the study. Parents/carers of CYP under 16 years of age will 
be asked to complete a parent/carer consent form. The 
young person will also be asked to sign an assent form 
to indicate their agreement. Consent will be asked from 
16–17 year- olds (using the Young Person Consent Form) 
but their parents will not. This is in line with Health 
Research Authority recommended processes.23
The study was approved by Yorkshire and the Humber–
South Yorkshire Research Ethics Committee (REC refer-
ence: 21/YH/0060; IRAS project ID: 293495).
It is possible that the questionnaires may make some 
vulnerable participants feel fatigued or distressed from 
completing questionnaires relating to their mental health 
and/or report serious symptoms that put them at imme-
diate risk. The research team will provide information 
on where to seek support and provide self- help informa-
tion. Unfortunately, the researchers are unable to provide 
medical advice. However, existing national surveys of chil-
dren’s mental health also follow this risk protocol.
Dissemination
Peer- reviewed publications, briefings for policymakers 
and lay summaries for participants and CYP and carers. 
Results will be made public, initially on a preprint server, 
and we will allow reuse of articles under a CC BY licence. 
The data set will be made publicly available.
Twitter Zahin Amin- Chowdhury @acciochoc
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